Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.
Molecular markers provide important biological and clinical information related to the classification of brain tumors, and the integration of relevant molecular parameters into brain tumor classification systems has been a widely discussed topic in neuro-oncology over the past decade. With recent advances in the development of clinically relevant molecular signatures and the 2016 World Health Organization (WHO) update, the views of the neuro-oncology community on such changes would be informative for implementing this process.



A survey with 8 questions regarding molecular markers in tumor classification was sent to an email list of Society for Neuro-Oncology members and attendees of prior meetings (n=5065). There were 403 respondents. Analysis was performed using whole group response, based on self-reported subspecialty.



The survey results show overall strong support for incorporating molecular knowledge into the classification and clinical management of brain tumors. Across all 7 subspecialty groups, ≥70% of respondents agreed to this integration. Interestingly, some variability is seen among subspecialties, notably with lowest support from neuropathologists, which may reflect their roles in implementing such diagnostic technologies.



Based on a survey provided to the neuro-oncology community, we report strong support for the integration of molecular markers into the WHO classification of brain tumors, as well as for using an integrated "layered" diagnostic format. While membership from each specialty showed support, there was variation by specialty in enthusiasm regarding proposed changes. The initial results of this survey influenced the deliberations underlying the 2016 WHO classification of tumors of the central nervous system.
MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Kenneth
K
Aldape
MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Romina
R
Nejad
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
David N
DN
Louis
MacFeeters-Hamilton Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Gelareh
G
Zadeh
D015415:Biomarkers / Q000378:metabolism*; D001932:Brain Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000378:metabolism; D016543:Central Nervous System Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D008495:Medical Oncology; D009462:Neurology; D017410:Practice Guidelines as Topic / Q000592:standards*; D011795:Surveys and Questionnaires; D014944:World Health Organization
D015415:Biomarkers
classification; molecular markers; pathology
Acta Neuropathol. 2014 Oct;128(4):561-71
25008768
J Clin Oncol. 2013 Jan 20;31(3):337-43
23071247
Acta Neuropathol. 2016 Jun;131(6):803-20
27157931
Acta Neuropathol Commun. 2016 Jan 13;4:4
26757882
Oncotarget. 2015 Oct 6;6(30):30295-305
26210286
Eur J Cancer. 2013 Nov;49(16):3477-85
23896377
J Neurooncol. 2015 Feb;121(3):489-97
25479829
Nat Genet. 2014 May;46(5):457-61
24705252
Neurology. 2014 Sep 23;83(13):1200-6
25150284
Front Oncol. 2015 Jun 30;5:147
26175967
Nat Genet. 2014 May;46(5):462-6
24705250
Neuro Oncol. 2016 Mar;18(3):388-400
26354927
J Neurooncol. 2015 May;122(3):441-50
25682093
Lancet Oncol. 2012 Sep;13(9):916-26
22877848
Cell. 2013 Oct 10;155(2):462-77
24120142
N Engl J Med. 2015 Jun 25;372(26):2481-98
26061751
J Neurooncol. 2015 Nov;125(2):249-51
26341371
Acta Neuropathol. 2015 May;129(5):669-78
25752754
Nat Genet. 2014 May;46(5):451-6
24705254
Cell. 2016 Jan 28;164(3):550-63
26824661
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
9776413
J Neurooncol. 2015 Jan;121(2):365-72
25344884
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
CNS Oncol. 2014 Nov;3(6):433-43
25438814
Acta Neuropathol. 2012 Dec;124(6):761-2
23151844
J Clin Oncol. 2006 Jun 20;24(18):2707-14
16782910
Brain Pathol. 2014 Sep;24(5):429-35
24990071
J Clin Oncol. 2006 Jun 20;24(18):2715-22
16782911
Lancet Oncol. 2012 Jul;13(7):707-15
22578793
Nat Genet. 2014 May;46(5):444-50
24705251
J Clin Oncol. 2013 Jan 20;31(3):344-50
23071237